GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation
Summary
A GSK plc release issued in London on 08 August 2025 on the US settlement of mRNA patent litigation between CureVac and BioNTech, reached on 7 August 2025. Under its existing license agreement with CureVac, GSK will receive an upfront settlement of $370 million, of which $320m is cash, and a 1% royalty on US sales by BioNTech and Pfizer of influenza, COVID-19 and related combination mRNA vaccines from the beginning of 2025. If the pending acquisition of CureVac by BioNTech closes, GSK would receive a further $130 million in cash and a 1% royalty on sales outside the US. GSK agreed to tender its approximately 16.6 million CureVac shares and will continue its own patent litigation against BioNTech and Pfizer.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Full text
08 August 2025 Issued: London, UK For media and investors only GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation Download (PDF - 143.0KB) - CureVac will make an upfront settlement of $370 million to GSK - GSK will receive a 1% royalty on future Pfizer / BioNTech US sales of influenza, COVID-19 and related combination mRNA vaccine products GSK plc (LSE/NYSE: GSK) today announces that, in connection with the mRNA patent settlement reached between CureVac and BioNTech on 7 August 2025, the Company will receive an upfront settlement of $370 million. GSK will also receive a 1% royalty in respect of US sales of influenza, COVID-19 and related combination mRNA vaccine products by BioNTech and Pfizer from the beginning of 2025. These payments are due to GSK in accordance with the terms of its existing license agreement with CureVac. Of the upfront settlement amount, $320m will be in cash. The remainder is attributed to the value of an amendment to GSK’s existing agreement with CureVac, which includes a significant reduction in royalties to be paid by GSK on our potential future mRNA influenza, COVID-19 and influenza/COVID-19 combination products. If the pending acquisition of CureVac by BioNTech successfully closes, the mRNA patent litigation between CureVac and BioNTech outside of the US will also be settled. GSK would then be entitled to an additional $130 million in cash and 1% royalty payments in respect of future sales outside of the US by BioNTech and Pfizer. GSK would also benefit from reduced milestones and a reduction in royalties payable in respect of GSK sales of mRNA influenza, COVID-19 and influenza/COVID-19 combination products outside of the US. The upfront settlement amount will be recorded as other operating income in GSK’s financial results as an adjusting item in the income statement in the third quarter of 2025. The 2025 and future royalty income will be recorded in total and core results in the income statements. This settlement does not impact GSK’s enforcement of its own patents against Pfizer and BioNTech in the U.S. and in Europe. GSK will continue with its litigation against BioNTech and Pfizer for infringement of GSK’s patents. Simultaneously with the settlement, GSK has entered into a customary tender and support agreement under which it has agreed to tender its approximately 16.6 million CureVac shares in the upcoming offer. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q2 Results for 2025. You might also like
File and source
- File
- gsk-provides-update-on-us-settlement-of-curevacbiontech-mrna-patent-litigation.html
- Size
- 478,227 bytes
- SHA-256
- bddd66409b74192cb8d8a832051e4bc8a85c283b0ebbf2aad5df1bf1f5bc3e66
- Original
- www.gsk.com